Stock Price Quote

AARTI DRUGS LTD.

NSE : AARTIDRUGSBSE : 524348ISIN CODE : INE767A01016Industry : Pharmaceuticals & DrugsHouse : Aarti
BSE487.60-4.9 (-0.99 %)
PREV CLOSE ( ) 492.50
OPEN PRICE ( ) 494.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 16757
TODAY'S LOW / HIGH ( )483.95 496.00
52 WK LOW / HIGH ( )310.8 645
NSE487.70-4.95 (-1 %)
PREV CLOSE( ) 492.65
OPEN PRICE ( ) 495.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 487.70 (256)
VOLUME 227756
TODAY'S LOW / HIGH( ) 483.75 496.60
52 WK LOW / HIGH ( )313.9 645.75
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-09 1984
Management Info
Prakash M Patil - Chairman Rashesh C Gogri - Managing Director
Registered Office

Address Plot No N 198,M I D C,Tarapur Village - Patembhi, Taluka Palghar,
Thane,
Maharashtra-401506

Phone 022-24019025

Email investorrelations@aartidrugs.com

Website www.aartidrugs.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

28Aug Post-Buyback Public Announcement
Ingra Ventures Pvt. Ltd ("Manager to the Buyback") has submiited to BSE..
28Aug Aarti Drugs informs about newspaper cl
Aarti Drugs has informed that the Post Buyback Public Announcement in co..
07Jul Aarti Drugs wins Pharmexcil Outstandin
Aarti Drugs has won Pharmexcil Outstanding Exports Award 2021-2022. The..
07Jul Aarti Drugs moves up on the BSE
Aarti Drugs is currently trading at Rs. 473.55, up by 3.25 points or 0.6..
02May Aarti Drugs informs about disclosure
Aarti Drugs has informed that it is not a Large Corporate as per the app..

Financials

in Millions
QTR Sep 23 ANNUAL 23
Net Profit345.81528.1
Gross Profit 468.3 2048.1
Operating Profit 661.62846.3
Net Sales 5775.424979.7

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2079.05 (4.05%)
M.Cap ( in Cr)1284.44
Sanofi India (BSE)
peergroup  8167.65 (0.84%)
M.Cap ( in Cr)18810.61
Alkem Laboratories (BSE)
peergroup  4651.65 (0.88%)
M.Cap ( in Cr)55617.45
Astrazeneca Pharma I (BSE)
peergroup  4833.80 (0.73%)
M.Cap ( in Cr)12084.50
Mankind Pharma (BSE)
peergroup  1948.10 (1.62%)
M.Cap ( in Cr)78038.63

Shareholding Pattern

PROMOTERS 58.56%
MUTUAL FUNDS/UTI 5.22%
NON-INSTITUTION 33.79%
FI/BANKS/INSURANCE 0.1%
GOVERNMENT 0%
FII 0%

About Aarti Drugs Ltd.

Aarti Drugs Ltd. was incorporated in the year 1984. Its today's share price is 487.6. Its current market capitalisation stands at Rs 4482.75 Cr. In the latest quarter, company has reported Gross Sales of Rs. 24979.7 Cr and Total Income of Rs.25002.02 Cr. The company's management includes Narendra J Salvi, Rushikesh Deole, Neha R Gada, Bhaskar Narayan Thorat, Ankit Paleja, Priti P Savla, Krishnacharya G Akamanchi, Navin C Shah, Uday M Patil, Harit P Shah, Harshit M Savla, Rashesh C Gogri, Prakash M Patil, Prakash M Patil, Chandrakant V Gogri.

It is listed on the BSE with a BSE Code of 524348 , NSE with an NSE Symbol of AARTIDRUGS and ISIN of INE767A01016. It's Registered office is at Plot No N 198,M I D C,Tarapur Village - Patembhi, Taluka PalgharThane-401506, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are GBCA & Associates, Gokhale & Sathe, Kirtane & Pandit LLP, Parikh Joshi & Kothare

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.